Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group |
| |
Authors: | C. Nicolaides M. A. Dimopoulos E. Samantas D. Bafaloukos C. Kalofonos G. Fountzilas E. Razi P. Kosmidis N. Pavlidis |
| |
Affiliation: | (1) Ioannina University Hospital, Ioannina, Greece;(2) Alexandra Hospital, Athens, Greece;(3) Agii Anargyri Cancer Hospital, Athens, Greece;(4) Metaxa Cancer Hospital, Piraeus, Greece;(5) University Hospital of Patras, Rio, Patras, Greece;(6) AHEPA Hospital, Thessaloniki, Greece;(7) HYGIA Hospital, Athens, Greece |
| |
Abstract: | Background:Gemcitabine and vinorelbine have shown activity inbreast cancer. A phase II trial was initiated in order to evaluate theresponse rate (RR) and time to progression (TTP) of the combination of the twodrugs in patients with metastatic breast cancer progressing after first-linetaxane-based chemotherapy.Patients and methods:Thirty-one patients were treated with thecombination of gemcitabine 1000 mg/m2 days 1 + 8 and vinorelbine30 mg/m2 days 1 + 8. The cycles were repeated every three weeks.Results:Of 27 evaluable patients 1 (4%, 95%confidence interval (95% CI): 0.1%–19%) achievedcomplete remission (CR), five (18%; 95% CI:6%–38%) partial remission (PR), eleven (40%;95% CI: 22%–61%) stable disease and ten patientsprogressed. The median duration of response was six months (range 4–10+)and the median duration of disease stabilization was five months (range2–22+). With a median follow-up of 16 months (range 0.4–22+) themedian TTP was 3.5 months (range 0.4–22+) and the median survival was9.5 months (range 0.4–22+). Grade 3–4 toxicities weregranulocytopenia 15 patients (48%), rash 3 patients (10%),neuropathy 1 patient (3%) and thrombocytopenia 1 patient (3%).In conclusion the combination of gemcitabine/vinorelbine in the dosesadministered in this group of patients had a response rate of 22% andneeds to be further evaluated in metastatic breast cancer. |
| |
Keywords: | advanced breast cancer chemotherapy gemcitabine vinorelbine |
本文献已被 Oxford SpringerLink 等数据库收录! |
|